India drugs giant rejects Novartis patent accusations
Published on Apr 4, 2014 11:27 PM
NEW DELHI (AFP) - Leading Indian drug company Biocon on Friday rejected allegations by Novartis that it infringed on the Swiss pharmaceutical giant's patent for its blockbuster diabetes drug Galvus.
Novartis announced on Thursday it was seeking an injunction in the Delhi High Court to stop Biocon from launching a generic version of Galvus, also known as Vildagliptin.
The suit against Biocon is the latest legal salvo in a campaign by global drugmakers against the nation's huge copycat drugs industry that the pharmaceutical companies say reduces incentives to produce cutting-edge medicines.
"Biocon has a reputation for respecting all valid IP (intellectual property) and intends to operate within the parameters of applicable IP laws in India and elsewhere," the Indian company said in an emailed statement to AFP.
To continue reading, log in if you are a subscriber
Enjoy 2 weeks of unlimited digital access to The Straits Times. Get your free access now!